Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9987990 | 0.84 | ESR1 (0.42) | ALDH1A1HPGDKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL16720201 | 0.81 | ALOX5 (0.45) | ALDH1A1HPGDKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL9650164 | 0.81 | NPC1 (0.35) | ALDH1A1HPGDKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL9988099 | 0.81 | TRPA1 (0.37) | ALDH1A1HPGDKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL16720178 | 0.81 | QDPR (0.44) | ALDH1A1HPGDKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL16720069 | 0.81 | EGFR (0.43) | KDM4EMAPTHSD17B10LMNARAB9A | |
| SCHEMBL9987901 | 0.79 | HSD17B1 (0.48) | ALDH1A1HSD17B10LMNACA12CA2 | |
| SCHEMBL16720369 | 0.78 | MKNK1 (0.37) | ALDH1A1HPGDKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL2373478 | 0.77 | SMN1; SMN2 (0.46) | ALDH1A1HPGDKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL16720402 | 0.77 | KMO (0.51) | ALDH1A1KDM4EMAPTLMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | claimed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | claimed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | claimed |
| US-5160504-A | Colorfastness to rubbing and light, metal-tanned leather | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-03 | — | — | US | claimed |
| US-5095100-A | Metal complex dyes and preparation thereof | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-10 | — | — | US | claimed |
| EP-3068758-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | The Wistar Institute Of Anatomy And Biology (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073864-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-6030975-A | ANTAGONIST OF ENDOTHELINS, I.E. INHIBITION OF BINDING WITH RECEPTOR; ANTITUMOR AND -CARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| US-5969134-A | CARDIOVASCULAR DISORDERS, VASOCONSTRICTION, HYPOTENSIVE AGENTS AND RELEASE OF ENDOTHELINS | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-19 | — | — | US | disclosed |
| US-5932730-A | Carboxylic acid derivatives, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | ALDH1A1 440/4885HPGD 163/4885KDM4E 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.